State of art and recent developments of anti-cancer strategies based on TRAIL

Stella Bernardi, Paola Secchiero, Giorgio Zauli

Research output: Contribution to journalArticlepeer-review


Multicellular organisms require apoptosis whereby the human body eliminates unnecessary and/or damaged cells. Apoptosis, or programmed cell death, can indeed be considered as a constitutive anti-cancer mechanism that seems to be defective in more than 50% of cancers. Molecular insights on the biology of the apoptotic process have led to the development of new anti-cancer strategies aiming at recovering and stimulating this process. Preclinical and clinical studies of our and other groups have demonstrated that targeting the extrinsic apoptotic pathway by various death receptors agonists is a safe and effective anti-cancer strategy, which thus may become a new cornerstone of cancer therapy. Here, we review the most recent acquisitions and patents on TRAIL or TRAIL mimetics, as well as the combination therapies that could be used with them.

Original languageEnglish
Pages (from-to)207-217
Number of pages11
JournalRecent Patents on Anti-Cancer Drug Discovery
Issue number2
Publication statusPublished - May 2012


  • Apoptosis
  • Apoptosis resistance
  • Combination therapy
  • Death receptors agonists
  • Extrinsic apoptotic pathway
  • Safety
  • TRAIL mimetics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)
  • Drug Discovery


Dive into the research topics of 'State of art and recent developments of anti-cancer strategies based on TRAIL'. Together they form a unique fingerprint.

Cite this